The CancerPrecision® panel was updated to reflect the latest scientific and medical findings. Both the gene list and the breakpoint enrichment for DNA-based gene fusion diagnostics have been updated. The set of pharmacogenetically relevant genes has also been expanded to include CACNA1S (anesthetic-induced malignant hyperthermia) and NUDT15 (drug-induced myelosuppression). The ability of CancerPrecision® to detect oncogenic viruses has been expanded: CancerPrecision® can now detect 22 strains of the human papillomavirus (HPV) as well as Merkel cell polyomavirus (MCV) and cytomegalovirus (CMV).
The panel for the diagnosis of gene fusions at RNA level, CancerFusionRx®, has also been updated. Here, the scope of the analyzed breakpoint regions has been expanded for the targeted detection of recurrent gene fusions. Similar to CancerPrecision®, the detection of expressed viral genes is now also possible at the RNA level. Thus, viral screening for HPV, EBV, MCV, and CMV infections can be carried out with the fusion panel alone. This means that more biomarkers with potential therapeutic relevance can be determined in one analysis from RNA.